Biofrontera Inc (BFRI) - Total Assets
Based on the latest financial reports, Biofrontera Inc (BFRI) holds total assets worth $15.41 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See BFRI total equity for net asset value and shareholders' equity analysis.
Biofrontera Inc - Total Assets Trend (2019–2024)
This chart illustrates how Biofrontera Inc's total assets have evolved over time, based on quarterly financial data.
Biofrontera Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Biofrontera Inc's total assets of $15.41 Million consist of 93.7% current assets and 6.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 26.7% |
| Accounts Receivable | $5.32 Million | 24.1% |
| Inventory | $6.65 Million | 30.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $35.00K | 0.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Biofrontera Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Biofrontera Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biofrontera Inc's current assets represent 93.7% of total assets in 2024, an increase from 81.6% in 2019.
- Cash Position: Cash and equivalents constituted 26.7% of total assets in 2024, up from 25.4% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 14.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 30.1% of total assets.
Biofrontera Inc Competitors by Total Assets
Key competitors of Biofrontera Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
Biofrontera Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.15 | 1.53 | 4.43 |
| Quick Ratio | 0.80 | 0.94 | 2.82 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.86 Million | $5.90 Million | $15.16 Million |
Biofrontera Inc - Advanced Valuation Insights
This section examines the relationship between Biofrontera Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.65 |
| Latest Market Cap to Assets Ratio | 0.42 |
| Asset Growth Rate (YoY) | -20.9% |
| Total Assets | $22.10 Million |
| Market Capitalization | $9.20 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biofrontera Inc's assets below their book value (0.42x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Biofrontera Inc's assets decreased by 20.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biofrontera Inc (2019–2024)
The table below shows the annual total assets of Biofrontera Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $22.10 Million | -20.88% |
| 2023-12-31 | $27.93 Million | -45.11% |
| 2022-12-31 | $50.88 Million | -4.39% |
| 2021-12-31 | $53.22 Million | +120.48% |
| 2020-12-31 | $24.14 Million | -16.05% |
| 2019-12-31 | $28.75 Million | -- |
About Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with t… Read more